Aptamers: A promising tool for cancer imaging, diagnosis, and therapy

Journal of Cellular Biochemistry

Volumn 114, Issue 2, 2013, Pages 250-255

  Liu, Kuancan ^a   Lin, Baoshun ^a   Lan, Xiaopeng ^a  

^a FUZHOU GENERAL HOSPITAL   (China)

Author keywords

Aptamers; Cancer diagnosis; Cancer imaging; Cancer therapy; Nanotechnology

Indexed keywords

A 10; APTAMER; AS 1411; BIOLOGICAL MARKER; CARBON NANOTUBE; CISPLATIN; CYTOTOXIC AGENT; DAUNORUBICIN; DNA APTAMER; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; KCHA 10; LIPOSOME; MACROGOL; MEMBRANE PROTEIN; MUCIN 1; NANOCONJUGATE; NANOPARTICLE; NUCLEOLIN; PEPTIDE APTAMER; POLYGLACTIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RNA APTAMER; SE 15 8; SGC 8; SMALL INTERFERING RNA; TD 05; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER THERAPY; CARCINOGENESIS; CHEMICAL MODIFICATION; COMBINATORIAL CHEMISTRY; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; DRUG RELEASE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; RNA SPLICING; TRANSCRIPTION REGULATION;

APTAMERS, NUCLEOTIDE; APTAMERS, PEPTIDE; DIAGNOSTIC IMAGING; HUMANS; NEOPLASMS; RNA, SMALL INTERFERING; SELEX APTAMER TECHNIQUE; STEM CELLS; TUMOR MARKERS, BIOLOGICAL;

HARNESS;

EID: 84872708922     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24373     Document Type: Article

References (57)

1. Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R, Farokhzad OC. 2007. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett 7:3065-3070.
2. Bala J, Bhaskar A, Varshney A, Singh AK, Dey S, Yadava P. 2011. In vitro selected RNA aptamer recognizing glutathione induces ROS mediated apoptosis in the human breast cancer cell line MCF 7. RNA Biol 8:101-111.
3. Brien G, Debaud AL, Bickle M, Trescol-Biemont MC, Moncorge O, Colas P, Bonnefoy-Berard N. 2011. Characterization of peptide aptamers targeting Bfl-1 anti-apoptotic protein. Biochemistry 50:5120-5129.
4. Bruno JG. 2010. Aptamer-biotin-streptavidin-C1q complexes can trigger the classical complement pathway to kill cancer cells. In Vitro Cell Dev Biol Anim 46:107-113.
5. Buerger C, Nagel-Wolfrum K, Kunz C, Wittig I, Butz K, Hoppe-Seyler F, Groner B. 2003. Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells. J Biol Chem 278:37610-37621.
6. Butz K, Denk C, Ullmann A, Scheffner M, Hoppe-Seyler F. 2000. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci USA 97:6693-6697.
7. Chang M, Yang CS, Huang DM. 2011. Aptamer-conjugated DNA icosahedral nanoparticles as a carrier of doxorubicin for cancer therapy. ACS Nano 5:6156-6163.
8. Chen X, Estevez MC, Zhu Z, Huang YF, Chen Y, Wang L, Tan W. 2009. Using aptamer-conjugated fluorescence resonance energy transfer nanoparticles for multiplexed cancer cell monitoring. Anal Chem 81:7009-7014.
9. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. 2008. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA 105:17356-17361.
10. Estevez MC, Huang YF, Kang H, O'Donoghue MB, Bamrungsap S, Yan J, Chen X, Tan W. 2010. Nanoparticle-aptamer conjugates for cancer cell targeting and detection. Methods Mol Biol 624:235-248.
11. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. 2004. Nanoparticle-aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res 64:7668-7672.
12. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. 2006. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103:6315-6320.
13. Herr JK, Smith JE, Medley CD, Shangguan D, Tan W. 2006. Aptamerconjugated nanoparticles for selective collection and detection of cancer cells. Anal Chem 78:2918-2924.
14. Hu Y, Duan J, Zhan Q, Wang F, Lu X, Yang XD. 2012. Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro. PLoS ONE 7:e31970.
15. Huang J, Moore J, Soffer S, Kim E, Rowe D, Manley CA, O'Toole K, Middlesworth W, Stolar C, Yamashiro D, Kandel J. 2001. Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. J Pediatr Surg 36:357-361.
16. Hwang do W, Ko HY, Lee JH, Kang H, Ryu SH, Song IC, Lee DS, Kim S. 2010. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nucl Med 51:98-105.
17. Kanwar JR, Roy K, Kanwar RK. 2011. Chimeric aptamers in cancer cell-targeted drug delivery. Crit Rev Biochem Mol Biol 46:459-477.
18. Kim MY, Jeong S. 2011. In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells. Nucleic Acid Ther 21:173-178.
19. Kim D, Jeong YY, Jon S. 2010a. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano 4:3689-3696.
20. Kim E, Jung Y, Choi H, Yang J, Suh JS, Huh YM, Kim K, Haam S. 2010b. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials 31:4592-4599.
21. Kim YH, Sung HJ, Kim S, Kim EO, Lee JW, Moon JY, Choi K, Jung JE, Lee Y, Koh SS, Rhee SG, Heo K, Kim IH. 2011. An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells. Cancer Lett 313:76-83.
22. Kim JK, Choi KJ, Lee M, Jo MH, Kim S. 2012. Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials 33:207-217.
23. Kunz C, Borghouts C, Buerger C, Groner B. 2006. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol. Mol Cancer Res 4:983-998.
24. Kwak H, Hwang I, Kim JH, Kim MY, Yang JS, Jeong S. 2009. Modulation of transcription by the peroxisome proliferator-activated receptor delta-binding RNA aptamer in colon cancer cells. Mol Cancer Ther 8:2664-2673.
25. Lee HK, Choi YS, Park YA, Jeong S. 2006. Modulation of oncogenic transcription and alternative splicing by beta-catenin and an RNA aptamer in colon cancer cells. Cancer Res 66:10560-10566.
26. Lee HK, Kwak HY, Hur J, Kim IA, Yang JS, Park MW, Yu J, Jeong S. 2007. beta-catenin regulates multiple steps of RNA metabolism as revealed by the RNA aptamer in colon cancer cells. Cancer Res 67:9315-9321.
27. Lee HS, Kim KS, Kim CJ, Hahn SK, Jo MH. 2009. Electrical detection of VEGFs for cancer diagnoses using anti-vascular endotherial growth factor aptamermodified Si nanowire FETs. Biosens Bioelectron 24:1801-1805.
28. Lee KY, Kang H, Ryu SH, Lee DS, Lee JH, Kim S. 2010. Bioimaging of nucleolin aptamer-containing 5-(N-benzylcarboxyamide)-2'-deoxyuridine more capable of specific binding to targets in cancer cells. J Biomed Biotechnol 2010:168306.
29. Liu G, Mao X, Phillips JA, Xu H, Tan W, Zeng L. 2009. Aptamer-nanoparticle strip biosensor for sensitive detection of cancer cells. Anal Chem 81:10013-10018.
30. Martin JA, Phillips JA, Parekh P, Sefah K, Tan W. 2011. Capturing cancer cells using aptamer-immobilized square capillary channels. Mol Biosyst 7:1720-1727.
31. Medley CD, Bamrungsap S, Tan W, Smith JE. 2011. Aptamer-conjugated nanoparticles for cancer cell detection. Anal Chem 83:727-734.
32. Mern DS, Hasskarl J, Burwinkel B. 2010a. Inhibition of Id proteins by a peptide aptamer induces cell-cycle arrest and apoptosis in ovarian cancer cells. Br J Cancer 103:1237-1244.
33. Mern DS, Hoppe-Seyler K, Hoppe-Seyler F, Hasskarl J, Burwinkel B. 2010b. Targeting Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest, and apoptosis in breast cancer cells. Breast Cancer Res Treat 124:623-633.
34. Mi J, Zhang X, Rabbani ZN, Liu Y, Reddy SK, Su Z, Salahuddin FK, Viles K, Giangrande PH, Dewhirst MW, Sullenger BA, Kontos CD, Clary BM. 2008. RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Mol Ther 16:66-73.
35. Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC. 2009. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 17:153-161.
36. Min K, Song KM, Cho M, Chun YS, Shim YB, Ku JK, Ban C. 2010. Simultaneous electrochemical detection of both PSMA (+) and PSMA (-) prostate cancer cells using an RNA/peptide dual-aptamer probe. Chem Commun (Camb) 46:5566-5568.
37. Mongelard F, Bouvet P. 2010. AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr Opin Mol Ther 12:107-114.
38. Nagel-Wolfrum K, Buerger C, Wittig I, Butz K, Hoppe-Seyler F, Groner B. 2004. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol Cancer Res 2:170-182.
39. Ni X, Zhang Y, Ribas J, Chowdhury WH, Castanares M, Zhang Z, Laiho M, DeWeese TL, Lupold SE. 2011. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest 121: 2383-2390.
40. Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehan M, Miller YE, Pass HI, Rom WN, Siegfried JM, Stewart A, Walker JJ, Weissfeld JL, Williams S, Zichi D, Brody EN. 2010. Unlocking biomarker discovery: Large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS ONE 5:e15003.
41. Reeb CA, Gerlach C, Heinssmann M, Prade I, Ceraline J, Roediger J, Roell D, Baniahmad A. 2011. A designed cell-permeable aptamer-based corepressor peptide is highly specific for the androgen receptor and inhibits prostate cancer cell growth in a vector-free mode. Endocrinology 152:2174-2183.
42. Savla R, Taratula O, Garbuzenko O, Minko T. 2011. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J Control Release 153:16-22.
43. Shangguan D, Cao Z, Meng L, Mallikaratchy P, Sefah K, Wang H, Li Y, Tan W. 2008. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J Proteome Res 7:2133-2139.
44. Shaw BR, Moussa L, Sharaf M, Cheek M, Dobrikov M. 2008. Boranophosphate siRNA-aptamer chimeras for tumor-specific downregulation of cancer receptors and modulators. Nucleic Acids Symp Ser (Oxf) 52:655-656.
45. Shi H, Tang Z, Kim Y, Nie H, Huang YF, He X, Deng K, Wang K, Tan W. 2010. In vivo fluorescence imaging of tumors using molecular aptamers generated by cell-SELEX. Chem Asian J 5:2209-2213.
46. Shi H, He X, Wang K, Wu X, Ye X, Guo Q, Tan W, Qing Z, Yang X, Zhou B. 2011. Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration. Proc Natl Acad Sci USA 108:3900-3905.
47. Shigdar S, Lin J, Yu Y, Pastuovic M, Wei M, Duan W. 2011. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci 102:991-998.
48. Smith JE, Medley CD, Tang Z, Shangguan D, Lofton C, Tan W. 2007. Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells. Anal Chem 79:3075-3082.
49. Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ. 2008. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res 68:2358-2365.
50. Taghdisi SM, Lavaee P, Ramezani M, Abnous K. 2011. Reversible targeting and controlled release delivery of daunorubicin to cancer cells by aptamerwrapped carbon nanotubes. Eur J Pharm Biopharm 77:200-206.
51. Takafuji Y, Jo JI, Tabata Y. 2011. Simple PEG modification of DNA aptamer based on copper ion coordination for tumor targeting. J Biomater Sci Polym Ed. 22:1179-1195.
52. Talbot LJ, Mi Z, Bhattacharya SD, Kim V, Guo H, Kuo PC. 2011. Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells. Surgery 150:224-230.
53. Tan L, Neoh KG, Kang ET, Choe WS, Su X. 2011. PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells. Macromol Biosci 11:1331-1335.
54. Tong R, Yala L, Fan TM, Cheng J. 2010. The formulation of aptamer-coated paclitaxel-polylactide nanoconjugates and their targeting to cancer cells. Biomaterials 31:3043-3053.
55. Wang KY, Zeng YL, Yang XY, Li WB, Lan XP. 2011. Utility of aptamerfluorescence in situ hybridization for rapid detection of Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 30:273-278.
56. Wu X, Ding B, Gao J, Wang H, Fan W, Wang X, Zhang W, Ye L, Zhang M, Ding X, Liu J, Zhu Q, Gao S. 2011. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int J Nanomedicine 6:1747-1756.
57. Yu C, Hu Y, Duan J, Yuan W, Wang C, Xu H, Yang XD. 2011. Novel aptamernanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS ONE 6:e24077.